{"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"41"}],"units":"Participants"}],"groups":[{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"BG000","title":"Normal Renal Function: Ixazomib"},{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"BG001","title":"Severe Renal Impairment: Ixazomib"},{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"BG002","title":"End-stage Renal Disease: Ixazomib"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.01","value":"54.5"},{"groupId":"BG001","spread":"7.35","value":"72.1"},{"groupId":"BG002","spread":"12.65","value":"61.3"},{"groupId":"BG003","spread":"12.01","value":"61.7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"41"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"25"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"16"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"41"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"35"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"41"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"27"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"12"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"41"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.28","value":"173.2"},{"groupId":"BG001","spread":"8.49","value":"160.8"},{"groupId":"BG002","spread":"9.61","value":"160.3"},{"groupId":"BG003","spread":"11.76","value":"167.1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"39"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Number analyzed is the number of participants with data available for height.","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"27.66","value":"98.1"},{"groupId":"BG001","spread":"14.70","value":"60.7"},{"groupId":"BG002","spread":"27.11","value":"86.0"},{"groupId":"BG003","spread":"28.85","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"41"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kg"}],"populationDescription":"Safety population is defined as participants who received at least 1 dose of study drug."}